

Symposium Neuroradiologicum

Cerebral Amyloid Angiopathy- related inflammation: an emerging disease

M. Savoiano, A. Erbetta, J.C. DiFrancesco, M. Brioschi, V. Silani, A. Falini, G. Storchi, L. Brighina, C. Ferrarese, N. Ticozzi, S. Messina, F. Girotti


Fondazione IRCCS Istituto Neurologico C. Besta, San Gerardo Hospital, Monza, University of Milano – Bicocca, University of Milan Medical School, IRCCS Istituto Auxologico Italiano, San Raffaele University and Hospital, Milan, Italy

Background

Orgogozo JM et al. Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization
Neurology 2003;61:46

- 372 AD patients were randomized: active immunization with amyloid (AN1792) or placebo
- Stop after 4 meningoencephalitides (ME)
- ME in 18/298 (6%) of immunized patients vs. 0/74 in pts with placebo

Orgogozo JM et al. Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. Neurology 2003;61:46



Eng JA et al. Clinical manifestation of cerebral amyloid angiopathy-related inflammation
Ann Neurol 2004;55:250

- of 42 pts with definite CAA, 7 had signs of inflammation, clinically manifested by cognitive impairment and epilepsy
- on imaging studies, they had white matter abnormalities
- apolipoprotein E genotype: $\epsilon 4/\epsilon 4$ in 71% (vs. 4%)
- good response to immunosuppressive treatment

Pt 1

History

A 76-year-old man, always in good health, with mildly elevated blood pressure, on Aspirin, comes to our outpatient clinic complaining of fatigue and “confusion in his head”.

Patient’s wife reports that he has some memory loss for the past few months.

Pt is a dental technician, still active at work, without problems



- Normal Neurological examination
- Funduscopy: mild arterial narrowing and sclerosis
- BP 160/80
- MMSE: 27/30 – (25.3/30 corrected for age and education, with some selective failure on memory tasks)
- Blood tests normal, including panel of antibodies, coagulation, inflammation

DIAGNOSIS





MILD COGNITIVE IMPAIRMENT

AMNESTIC MCI



CT Sept. 10, 2008




MR 0.5T Sept.11, 2008





MR - FLAIR




MR 1.5T Sept.11,2008
DWI (ADC)



Post-contrast






MR perfusion (CBV)





A diagnostic examination was performed.

no hemorrhages in the basal ganglia



1.5T



11/9/08





GE

T2*

T2*



T2*



Boston Criteria

for the clinical diagnosis of CAA

Knudsen KA et al. Neurology 2001,56:537-539



- Definite (post-mortem or biopsy)
- Probable with pathologic support (biopsy)
- Probable: clinical data + MRI or CT with
 - multiple lobar hemorrhages, cortical or cortico-subcortical
 - age ≥ 55 years
 - no other causes for hemorrhages
- Possible: same criteria, but single hemorrhage

Diagnosis: CAA-related inflammation


Steroid therapy was promptly instituted:


Dexamethasone 8 mg/d i.m. for 1 wk, 4 mg/d in the 2nd wk, then tapering with oral prednisone

Control MRI after 35 days (Oct 16, 2008)




Oct 16, 2008







Control MRI
4 months later
(Feb 16, 2009)



T2*



- Normal neurological examination
- Normal cognitive profile
- MMSE 30/30
- APOE genotype: $\epsilon 4$ - $\epsilon 4$

CAA + good response to steroid
and $\epsilon 4$ - $\epsilon 4$ genotype




CAA-ri


Patient 2

- A 67-years-old man with progressive, severe neurologic involvement, with memory and attention deficit and mood disorder. No focal signs
- Normal laboratory findings


Pt. 2 MRI at presentation




ADC



Post
contrast








Pt. 2 MRI post left frontal biopsy and steroid treatment




- Brain biopsy: unremarkable
- Good response to steroids

GE sequences solve the diagnostic problem



→ $\epsilon_4 - \epsilon_4$





Anti-Aβ 1-40 and 1-42 autoantibodies in CSF may become the biomarker of CAA-ri

Di Francesco JC et al.
Neurology, in press

Patient 3



- A 68-year-old woman with acute onset of speech difficulties and right hemiparesis was found to have a single left posterior temporal lesion. Extensive workup was negative. Biopsy refused. Disappearance of lesion after steroid therapy

Pt 3







T2-wi

Post-steroid
therapy





FLAIR



GE T2*

SWI



Two aspects:

1. Multifocal Leucoencephalopathy
consistent with an
autoimmune/inflammatory reaction

and

2. Cortico-subcortical
Microhemorrhages compatible with
cerebral amyloid angiopathy

Take-home message:

- GE T2* or SWI are essential to diagnose CAA
- Response to steroid therapy and
- APOE $\epsilon 4/\epsilon 4$ genotype support diagnosis of CAA-related inflammation
- Anti-A β autoantibodies in CSF may become the biomarker of the disease

There is a spectrum extending from

Cerebral amyloid angiopathy (CAA)- related inflammation

to



CAA-related angiitis

Amyloid β -related inflammation

A β -related angiitis (ABRA)

Greenberg SM et al. Neurology 2007;68:782

Scolding NJ et al. Brain 2005;128:500



Thank you for your attention!